Study in Patients With Asthma

Dey1 site in 1 country32 target enrollmentJuly 2002

ConditionsAsthma

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Asthma
Sponsor: Dey
Enrollment: 32
Locations: 1
Primary Endpoint: Primary: The primary efficacy outcome is measure of lung function.
Status: Completed
Last Updated: 15 years ago

The purpose of this study is to determine which dose of the investigational drug is safest and most effective compared to the control group.

Registry

clinicaltrials.gov

Start Date

July 2002

End Date

November 2005

Last Updated

15 years ago

Study Type

Interventional

Study Design

Crossover

Sex

All

Sponsor

Dey

•Require the regular use of an inhaled beta-2-selective adrenergic agent.
•No clinically significant abnormalities on the medical history, physical examination, and clinical laboratory tests.

•Active acute or chronic disorders of the respiratory system within one month prior to screening.
•Smoking history within the past 12 months or greater than a lifetime 10 pack-year smoking history.
•Debilitating systemic and/or life-threatening diseases.

Primary: The primary efficacy outcome is measure of lung function.

Secondary: Change in lung function will be examined as a secondary efficacy outcome, as well as vital signs, physical examination, adverse event reporting,etc.